AU2015301579B2 - Dendrimer compositions and use in treatment of neurological and CNS disorders - Google Patents

Dendrimer compositions and use in treatment of neurological and CNS disorders Download PDF

Info

Publication number
AU2015301579B2
AU2015301579B2 AU2015301579A AU2015301579A AU2015301579B2 AU 2015301579 B2 AU2015301579 B2 AU 2015301579B2 AU 2015301579 A AU2015301579 A AU 2015301579A AU 2015301579 A AU2015301579 A AU 2015301579A AU 2015301579 B2 AU2015301579 B2 AU 2015301579B2
Authority
AU
Australia
Prior art keywords
dendrimer
dendrimers
brain
pct
pamam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015301579A
Other languages
English (en)
Other versions
AU2015301579A1 (en
Inventor
William BAUMGARTNER
Mary E. Blue
Michael V. JOHNSTON
Sujatha Kannan
Elizabeth NANCE
Kannan Rangaramanujam
Barbara Slusher
Mary Ann Wilson
Fan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Kennedy Krieger Institute Inc
Original Assignee
Johns Hopkins University
Kennedy Krieger Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, Kennedy Krieger Institute Inc filed Critical Johns Hopkins University
Publication of AU2015301579A1 publication Critical patent/AU2015301579A1/en
Application granted granted Critical
Publication of AU2015301579B2 publication Critical patent/AU2015301579B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
AU2015301579A 2014-08-13 2015-08-13 Dendrimer compositions and use in treatment of neurological and CNS disorders Active AU2015301579B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462036675P 2014-08-13 2014-08-13
US201462036839P 2014-08-13 2014-08-13
US62/036,839 2014-08-13
US62/036,675 2014-08-13
PCT/US2015/045112 WO2016025745A1 (en) 2014-08-13 2015-08-13 Dendrimer compositions and use in treatment of neurological and cns disorders

Publications (2)

Publication Number Publication Date
AU2015301579A1 AU2015301579A1 (en) 2017-02-16
AU2015301579B2 true AU2015301579B2 (en) 2018-08-09

Family

ID=54062806

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015301579A Active AU2015301579B2 (en) 2014-08-13 2015-08-13 Dendrimer compositions and use in treatment of neurological and CNS disorders

Country Status (7)

Country Link
US (1) US20170232120A1 (ja)
EP (1) EP3180032A1 (ja)
JP (1) JP6531164B2 (ja)
CN (2) CN114392360A (ja)
AU (1) AU2015301579B2 (ja)
CA (1) CA2957940C (ja)
WO (1) WO2016025745A1 (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
CA2946422C (en) 2014-04-30 2019-03-05 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
US10918720B2 (en) 2014-08-13 2021-02-16 The Johns Hopkins University Selective dendrimer delivery to brain tumors
AU2016211696B2 (en) 2015-01-27 2018-05-10 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
WO2017075580A1 (en) * 2015-10-29 2017-05-04 The Johns Hopkins University Compositions and methods for treatment of peroxisomal disorders and leukodystrophies
EP3532532A4 (en) * 2016-10-27 2020-06-03 Virginia Commonwealth University Intellectual Property Foundation CARBON HYDRATE FUNCTIONALIZED NANOPARTICLES AND USES THEREOF
US11160881B2 (en) 2017-04-27 2021-11-02 The Johns Hopkins University Dendrimer compositions for use in angiography
AU2018365250B2 (en) * 2017-11-10 2022-05-26 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
CA3163892A1 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye
US20230226199A1 (en) * 2019-12-04 2023-07-20 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery
WO2021113657A1 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Triantennary n-acetylgalactosamine modified hydroxyl polyamidoamine dendrimers and methods of use thereof
EP4138922A1 (en) 2020-04-24 2023-03-01 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for treatment of severe acute respiratory distress syndrome
EP4138821A1 (en) 2020-04-24 2023-03-01 The Johns Hopkins University Compositions and methods comprising dendrimers and therapeutic agents
WO2022192135A1 (en) * 2021-03-08 2022-09-15 Transdermal Biotechnology, Inc. Dendrimer-n-actyl-l-cysteine conjugates for treatment or prevention of aging skin or other indications
AU2022349065A1 (en) 2021-09-21 2024-04-04 The Johns Hopkins University Dendrimer conjugates of small molecule biologics for intracellular delivery
WO2023122599A1 (en) 2021-12-20 2023-06-29 The Johns Hopkins University Glycosylated dendrimers for targeted intracellular delivery
WO2023154939A2 (en) * 2022-02-14 2023-08-17 The Johns Hopkins University Gcpii inhibition for the treatment of sarcopenia and aging
WO2024020597A1 (en) 2022-07-22 2024-01-25 The Johns Hopkins University Dendrimer-enabled targeted intracellular crispr/cas system delivery and gene editing
WO2024044776A1 (en) 2022-08-26 2024-02-29 The Johns Hopkins University Cannabinoid dendrimer compositions for targeted delivery
WO2024044756A1 (en) 2022-08-26 2024-02-29 The Johns Hopkins University Dendrimer compositions for targeted delivery of psychedelic therapeutics
WO2024044760A1 (en) 2022-08-26 2024-02-29 The Johns Hopkins University Dendrimer conjugates of antidepressant and antipsychotic agents and their methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2214646T3 (pl) * 2007-10-05 2021-12-20 Wayne State University Dendrymery do przedłużonego uwalniania związków
WO2009142754A1 (en) * 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
WO2010039861A2 (en) * 2008-09-30 2010-04-08 The Regents Of The University Of Michigan Dendrimer conjugates
WO2010147831A1 (en) * 2009-06-15 2010-12-23 Wayne State University Dendrimer based nanodevices for therapeutic and imaging purposes
WO2011011384A2 (en) * 2009-07-20 2011-01-27 The Regents Of The University Of Michigan Synthesis of dendrimer conjugates
CA2830052C (en) * 2010-03-31 2018-10-09 Wayne State University Injectable dendrimer hydrogel nanoparticles
US20130224110A1 (en) * 2010-09-16 2013-08-29 Cornell University Use of adenosine receptor signaling to modulate permeability of blood-brain barrier

Also Published As

Publication number Publication date
AU2015301579A1 (en) 2017-02-16
CN114392360A (zh) 2022-04-26
US20170232120A1 (en) 2017-08-17
WO2016025745A9 (en) 2016-04-07
JP2017529325A (ja) 2017-10-05
CN106659798A (zh) 2017-05-10
CA2957940A1 (en) 2016-02-18
WO2016025745A1 (en) 2016-02-18
EP3180032A1 (en) 2017-06-21
JP6531164B2 (ja) 2019-06-12
CA2957940C (en) 2020-05-26

Similar Documents

Publication Publication Date Title
AU2015301579B2 (en) Dendrimer compositions and use in treatment of neurological and CNS disorders
Feng et al. Neutrophil-like cell-membrane-coated nanozyme therapy for ischemic brain damage and long-term neurological functional recovery
Huang et al. GM1-modified lipoprotein-like nanoparticle: Multifunctional nanoplatform for the combination therapy of Alzheimer’s disease
Ramanathan et al. Theranostic applications of nanoparticles in neurodegenerative disorders
Cano et al. Current advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases
Song et al. Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer’s disease by accelerating the clearance of amyloid-beta
Mishra et al. Dendrimer brain uptake and targeted therapy for brain injury in a large animal model of hypothermic circulatory arrest
JP6342575B2 (ja) 脳腫瘍への選択的デンドリマー送達
JP7108306B2 (ja) デンドリマー組成物ならびに壊死性腸炎および他の胃腸障害の処置における使用
Dalpiaz et al. Brain uptake of a Zidovudine prodrug after nasal administration of solid lipid microparticles
Kim et al. Potential Alzheimer's disease therapeutic nano-platform: Discovery of amyloid-beta plaque disaggregating agent and brain-targeted delivery system using porous silicon nanoparticles
Yang et al. mTOR-mediated immunometabolic reprogramming nanomodulators enable sensitive switching of energy deprivation-induced microglial polarization for Alzheimer’s disease management
Nguyen et al. Therapeutic strategies and nano-drug delivery applications in management of aging Alzheimer’s disease
Chintapula et al. Immunomodulation in age‐related disorders and nanotechnology interventions
Karande et al. Novel approaches for the delivery of biologics to the central nervous system
Ansari et al. Multifunctional Nanocarriers for Alzheimer’s Disease: Befriending the Barriers
Liaw et al. Assessment of the Oral Delivery of a Myelin Basic Protein Gene Promoter with Antiapoptotic bcl-xL (pMBP-bcl-xL) DNA by Cyclic Peptide Nanotubes with Two Aspect Ratios and Its Biodistribution in the Brain and Spinal Cord
Pathak et al. Drug delivery to the brain: targeting technologies to deliver therapeutics to brain lesions
Upadhaya et al. Diagnostic and theranostic intranasal nanointerventions for brain diseases
Yanamadala Peptide Carriers to Improve Uptake and Functionality and to Cross BBB to Arrest Secondary Injury Post TBI
Zhang Kinetics of polymeric nanoparticulate carriers and cargo under physiological and pathological conditions in the retina
Bhattacharya Extravaganza of Nanobiotechnology in the Diagnosis and Treatment of Dementia Patients
Hussain et al. Alzheimer's Disease: Pathophysiology and towards Rational Drug Treatment
Tyler Treating acute spinal cord injury with methylprednisolone modified and loaded glycol chitosan nanocarriers

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)